At least 13 companies reduced their workforces during the second quarter, compared to at least nine in 2Q12. All cash and operating loss figures in $M. (A) Cash, cash equivalents, other current financial assets and restricted cash; (B) Nine-month net cash burn at Sept. 30, 2012; (C) 12-month operating loss at Dec. 31, 2012; NA = not applicable; ND = not disclosed

Date

Company

Staff cuts

Cash

Yrs cash pre-cut

Cash date

3-mo op loss ended 3/31

4/8/13 & 6/26/13

Delcath Systems Inc. (NASDAQ:DCTH)

~37%

$42.8

1.05

3/31/13

$10.2

Delcath announced a 21% reduction in headcount in April followed by a further 20% reduction in June. The company had 92 employees at Dec. 31, 2012. The company is focusing on the development and commercialization of its Melblez Kit chemosaturation system. Deltcath expects cash spending for the 4Q13 to be about $6-$8M. In May, an FDA panel voted against the approval of Melblez Kit to treat unresectable ocular melanoma that is metastatic to the liver. The product has a Sept. 13 PDUFA date.

4/8/13

Unigene Laboratories Inc. (OTCBB:UGNE)

40% to 31

$1.1

0.05

3/31/13

$5.4

Cuts came from recombinant calcitonin production operations and manufacturing of osteoporosis drug Fortical calcitonin, an osteoclast inhibitor marketed in the U.S. by Upsher-Smith Laboratories Inc. The cash figure includes $750,000 raised in an April private placement of senior notes.